Logo image of PTIX

PROTAGENIC THERAPEUTICS INC (PTIX) Stock Fundamental Analysis

NASDAQ:PTIX - Nasdaq - US74365N2027 - Common Stock - Currency: USD

3.32  -0.2 (-5.68%)

After market: 3.3112 -0.01 (-0.27%)

Fundamental Rating

0

PTIX gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 557 industry peers in the Biotechnology industry. Both the profitability and financial health of PTIX have multiple concerns. PTIX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year PTIX has reported negative net income.
PTIX had a negative operating cash flow in the past year.
In the past 5 years PTIX always reported negative net income.
In the past 5 years PTIX always reported negative operating cash flow.
PTIX Yearly Net Income VS EBIT VS OCF VS FCFPTIX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M -5M

1.2 Ratios

Looking at the Return On Assets, with a value of -530.09%, PTIX is doing worse than 96.60% of the companies in the same industry.
Industry RankSector Rank
ROA -530.09%
ROE N/A
ROIC N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTIX Yearly ROA, ROE, ROICPTIX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 1K -1K -1.5K

1.3 Margins

PTIX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PTIX Yearly Profit, Operating, Gross MarginsPTIX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

PTIX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PTIX has more shares outstanding
There is no outstanding debt for PTIX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PTIX Yearly Shares OutstandingPTIX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K 500K
PTIX Yearly Total Debt VS Total AssetsPTIX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

Based on the Altman-Z score of -70.08, we must say that PTIX is in the distress zone and has some risk of bankruptcy.
PTIX has a worse Altman-Z score (-70.08) than 95.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -70.08
ROIC/WACCN/A
WACCN/A
PTIX Yearly LT Debt VS Equity VS FCFPTIX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M

2.3 Liquidity

A Current Ratio of 0.86 indicates that PTIX may have some problems paying its short term obligations.
PTIX has a worse Current ratio (0.86) than 89.27% of its industry peers.
A Quick Ratio of 0.86 indicates that PTIX may have some problems paying its short term obligations.
PTIX has a worse Quick ratio (0.86) than 88.91% of its industry peers.
Industry RankSector Rank
Current Ratio 0.86
Quick Ratio 0.86
PTIX Yearly Current Assets VS Current LiabilitesPTIX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

0

3. Growth

3.1 Past

PTIX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 30.70%, which is quite impressive.
EPS 1Y (TTM)30.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PTIX Yearly EPS VS EstimatesPTIX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PTIX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PTIX Price Earnings VS Forward Price EarningsPTIX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTIX Per share dataPTIX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6 -8 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PTIX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PROTAGENIC THERAPEUTICS INC

NASDAQ:PTIX (6/13/2025, 8:00:01 PM)

After market: 3.3112 -0.01 (-0.27%)

3.32

-0.2 (-5.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13
Earnings (Next)08-12 2025-08-12
Inst Owners5.13%
Inst Owner Change125.3%
Ins Owners9.59%
Ins Owner Change0%
Market Cap2.89M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.02
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-13.31
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-4.17
FCFYN/A
OCF(TTM)-4.17
OCFYN/A
SpS0
BVpS-0.1
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -530.09%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-147.64%
ROA(5y)-153.54%
ROE(3y)-244.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.86
Quick Ratio 0.86
Altman-Z -70.08
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)30.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%49.4%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-87.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.84%
OCF growth 3YN/A
OCF growth 5YN/A